BioTime Inc (BTX)

2.57
0.06 2.30
AMEX : Health Care
Prev Close 2.63
Open 2.62
Day Low/High 2.58 / 2.71
52 Wk Low/High 2.00 / 4.10
Volume 151.21K
Avg Volume 369.80K
Exchange AMEX
Shares Outstanding 115.80M
Market Cap 306.88M
EPS 0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioTime Reports Second Quarter Results And Recent Corporate Accomplishments

BioTime Reports Second Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the second quarter ended June 30,...

AgeX Therapeutics Obtains $10 Million In Capital And Commences Operations

AgeX Therapeutics Obtains $10 Million In Capital And Commences Operations

AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc.

BioTime Receives DSMB Approval To Start Third Patient Cohort In Clinical Trial For Dry-AMD; Commences Patient Enrollment In The US

BioTime Receives DSMB Approval To Start Third Patient Cohort In Clinical Trial For Dry-AMD; Commences Patient Enrollment In The US

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that the Data Safety Monitoring Board (DSMB) has authorized the...

BioTime, Inc. To Announce Second Quarter 2017 Results On August 2, 2017

BioTime, Inc. To Announce Second Quarter 2017 Results On August 2, 2017

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release second quarter financial and operating...

Data From BioTime's Phase I/IIa OpRegen® Trial To Be Presented At The 2017 American Academy Of Ophthalmology (AAO) Annual Meeting

Data From BioTime's Phase I/IIa OpRegen® Trial To Be Presented At The 2017 American Academy Of Ophthalmology (AAO) Annual Meeting

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that an abstract related to the Company's retinal tissue...

BioTime To Host Key Opinion Leader Event On The Topic Of Dry AMD In New York City

BioTime To Host Key Opinion Leader Event On The Topic Of Dry AMD In New York City

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, announced today that it will host a Key Opinion Leader event on the topic of...

BioTime Subsidiary AgeX Therapeutics Appoints Aubrey De Grey, Ph.D. As VP Of New Technology Discovery

BioTime Subsidiary AgeX Therapeutics Appoints Aubrey De Grey, Ph.D. As VP Of New Technology Discovery

AgeX Therapeutics ("AgeX"), a subsidiary of BioTime, Inc. (NYSE MKT:BTX) with a focus on developing new therapies in the field of biomedical gerontology, today announced the appointment of distinguished researcher and...

Hadasit Bio-Holdings (HBL) And BioTime Complete Shares Swap Transaction In Cellcure Neurosciences

As part of the transaction, HBL, which owns 21% of Cellcure's share capital, will sell its entire holdings to BioTime, Inc., In exchange, BioTime will pay $12.75 million in Biotime shares to HBL

Biotime Expands & Advances Ophthalmology Portfolio

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported several developments for its ophthalmology portfolio including:...

BioTime's Renevia® Achieves Primary Endpoint In European Pivotal Trial

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported that, based on the analysis of top line data, the Renevia®...

BioTime To Announce Top Line Data From The Company's Renevia European Pivotal Trial

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will report the top line data from the Company's...

BioTime Co-CEO Dr. Michael West To Deliver Presentation As Part Of Biotech Panel At Mauldin Economics' Strategic Investment Conference On May 24

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D.

BioTime Presents Retinal Restoration Data At ARVO

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that a poster related to the Company's retinal restoration...

BioTime, Inc. Reports First Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the first quarter ended...

BioTime Announces New Positive Data From OpRegen® Trial In Dry-AMD

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced new data from the Phase I/IIa clinical trial...

BioTime Co-CEO Dr. Michael D. West To Present At World Advanced Therapies & Regenerative Medicine Congress On May 17 And 19

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D.

BioTime, Inc. To Announce First Quarter 2017 Results On May 10, 2017

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release first quarter financial and operating...

BioTime To Present Additional Data At Upcoming ARVO

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that an abstract related to the Company's retinal tissue...

BioTime Forms New Subsidiary AgeX Therapeutics, Inc. To Develop Its Programs Focused On Human Aging

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the formation of AgeX Therapeutics, Inc.

BioTime Co-CEO Dr. Michael West To Deliver Keynote Presentation At GTC Bio Stem Cell Summit On April 6

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D.

Key BioTime Patents Upheld By European Patent Office

BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company developing and commercializing products addressing degenerative disease, today announced the successful defense of two key patents from challenge before...

BioTime To Present At Oppenheimer 27th Annual Healthcare Conference

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will be...

BioTime, Inc. Reports Fourth Quarter And Fiscal Year 2016 Financial Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the fourth quarter and year...

Data From BioTime's OpRegen® Trial In Dry-AMD To Be Presented At ARVO On May 8

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that a poster presentation based on data from its Phase...

BioTime Expands OpRegen® Clinical Trial In Dry-AMD With Opening Of First US Sites

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the expansion of its ongoing Phase I/IIa clinical trial for...

BioTime, Inc. To Announce Fourth Quarter And Fiscal 2016 Results On March 16, 2017

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release fourth quarter and fiscal 2016 financial...

BioTime Reports Pro Forma Gain On Deconsolidation Of OncoCyte Subsidiary

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the deconsolidation of OncoCyte Inc.